Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 11:34 PM
Ignite Modification Date:
2025-12-25 @ 9:23 PM
NCT ID:
NCT01168856
Group ID:
EG000
Title:
Resistance Monitoring Arm
Description:
Participants enrolled into this study were those with Hepatitis C Virus (HCV) infection who participated in one of the following studies (NV20536 \[NCT00869661\], NV21075 \[NCT00963885\], WV21913 \[NCT01331850\], NV22621 \[NCT01057667\], NP22660 \[NCT01185860\], NV22688 \[NCT01168856\], NV22776 \[NCT01220947\], PP25213 \[NCT01278134\], NV27779 \[NCT01482390\], NV27780 \[NCT01482403\], NP27946 \[NCT01483742\], YV28218 \[NCT01749150\], NP28266 \[NCT01628094\]) and had developed direct acting antiviral (DAA)-associated resistant mutation(s), which persisted through to the last evaluation of drug resistance in the donor protocol(s), or achieved only a partial viral response or experienced a viral breakthrough while on mericitabine treatment not associated with selection of S282T resistance mutations.
Deaths Number Affected:
None
Deaths Number At Risk:
None
Serious Number Affected:
0
Serious Number At Risk:
172
Other Number Affected:
1
Other Number At Risk:
172
Study:
NCT01168856
Results Section:
NCT01168856
Adverse Events Module:
NCT01168856